AARDEX Group

Author Archives: Bernard Vrijens

smart pill bottles

Harnessing Smart Pill Bottles to Improve Patient Adherence in Clinical Research

“Nothing stops a drug from working like not taking it, making patient adherence one of the most important factors to consider when designing a clinical trial.”  – Bernard Vrijens, Scientific Lead, AARDEX® Group Poor patient adherence is a problem that has … Read More

The Role of Medication Adherence Tools

The Heart of the Matter: The Role of Medication Adherence Tools in Tackling the CVD Epidemic

Despite huge strides in how cardiovascular diseases (CVD) are treated in recent years, the conditions remain among the leading causes of morbidity and mortality worldwide. At least part of the problem is that even the most effective drugs will not … Read More

Smart Pills

AARDEX® Group adds etectRx’s Smart Pills to their MEMS® Adherence Hardware ecosystem 

The partnership sees the integration of AARDEX’s adherence analytics software with etectRx’s ingestible adherence sensor smart pill. Liege, Belgium (APRIL 28, 2022) – Belgium-based AARDEX Group, the leader in measuring and managing medication adherence in clinical trials today announced a strategic … Read More

Drug Forgiveness and Patient Adherence

Exploring the Relationship Between Drug Forgiveness and Patient Adherence

With patient adherence thought to be lower than 50% 1, drug companies are increasingly maximizing dosages to bridge the gap at population scale – but are we overdosing individual patients as a result? The industry’s tendency to always aim for the … Read More

FDA Diversity Guidance

FDA Issues Draft Diversity Guidance to Improve Enrollment of Participants from Underrepresented Patient Populations

Diversity in clinical research is a growing concern for sponsors as many factors can influence how an individual may react to certain drugs: age, biological sex, disabilities, chronic comorbidities, geographical location, gender identity, race, and ethnic background.  Thus, if the … Read More

Protocol Deviations in Decentralized Trials

Optimizing Study Design to Tackle Protocol Deviations in DCTs

Decentralized Clinical Trials (DCTs) are here to stay, as demonstrated by international regulators’ recent commitments to the model. But while the approach offers a multitude of benefits, from expanding access to increasing cohort diversity, it can also serve to magnify … Read More

Harnessing Digital Health Technology to Bolster Study Power

In a world of big tech, data is king. This slogan is far from news for the Biopharmaceutical Industry, but clinical trials are lengthy, complex, and expensive, meaning precious information isn’t always utilized to its maximum potential. In recent years, … Read More

FDA DHT Guidance | AARDEX Industry Insights

AARDEX Industry Insights: Pharma Responds to FDA’s Draft DHT Guidance | EU Clinical Trials Regulation

It’s hard to believe that we are already a full quarter into 2022 – and a busy one it’s been -particularly for the regulatory landscape. AARDEX® Group also announced the first in a series of virtual events, a live panel debate … Read More

FDA DHT Guidance

Industry Stakeholders Respond to FDA’s Draft Digital Health Technology Guidance

In December last year, the Food and Drug Administration (FDA) issued new draft guidance (Digital Health Technologies for Remote Data Acquisition in Clinical investigations) on what kinds of devices and software may be used for remote monitoring of clinical trial … Read More

innovative health initiative

Innovative Health Initiative Pledges to Help Break Silos Between Basic Research, Medical Disciplines, and Technological Areas.

Technology presents the healthcare community with a golden opportunity to improve lives – but only if we embrace that potential. Success, according to the Innovative Health Initiative’s Strategic Research and Innovation Agenda, depends on cross-sector collaboration. Across Europe, healthcare faces … Read More